Transparency Market Research Report Added "Uterine fibroid treatment Market" to its database.
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters.
The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy.
Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant.
The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy.
Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
Obtain Report Details: www.transparencymarketresearch.com…tment-market.html
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
The market for uterine fibroid are divided based on non-hormonal treatment, hormonal treatment, surgical methods and geographically. Non-hormonal treatment are subdivided into non-steroidal anti-inflammatory agents (NSAIDS).
Hormonal treatment segmented as Oral contraceptives, Progestins/Antiprogestins, Gonadotropin-releasing hormone (GnRH) agonists. Surgical Methods are segmented as traditional abdominal myomectomy, laparoscopic or robotic myomectomy, hysteroscopic myomectomy, hysterectomy, uterine artery embolization or fibroid embolization (UAE) and ablation.
Some of Major players in uterine fibroid market are Boston Scientific Corporation, Cooper Surgical, C.R. Bard, F. Hoffmann-La Roche Ltd, GE Healthcare, Karl Storz Endoscopy, Richard Wolf Medical Instruments and Siemens Medical Solutions, AbbVie Inc., AstraZeneca, Bayer AG, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer Inc., Johnson & Johnson and Novartis AG.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.
The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Category: Market Research Publishers and RetailersCompany profile: TMR provides a range of marketing and business research solutions designed for your specific needs. From off-the-shelf syndicated business And market research to made-to-order custom research, we serve our clients to fulfill their immediate as well as ongoing research requirements. We specialize in the following areas: Syndicated Research Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverage ...
For more information:Make an Inquiry about this report HERE!